Chitosan (Cs) as a hemostatic agent has been in use to control hemorrage. Composite hydrogel formed by entrapment of vasoconstrictor-potassium aluminium sulfate (0.25 %PA) and coagulation activator-calcium chloride (0.25 %Ca) into Cs (2 %) hydrogel would enhance the hemostatic property of Cs. In this work, the prepared composite hydrogel was injectable, shear thinning, cyto and hemocompatible. The 2 %Cs-0.25 %PA-0.25 %Ca composite hydrogel caused rapid blood clotting by accelerating RBC/platelet aggregation and activation of the coagulation cascade. Further, in vivo studies on rat liver and femoral artery hemorrage model showed the efficiency of 2 %Cs-0.25 %PA-0.25 %Ca composite hydrogel to achieve hemostasis in a shorter time (20 ± 10 s, 105 ± 31 s) than commercial hemostatic agents-Fibrin sealant (77 ± 26 s, 204 ± 58 s) and Floseal (76 ± 15 s, 218 ± 46 s). In in vivo toxicological study, composite hydrogel showed material retention even after 8 weeks post-surgery, therefore excess hydrogel should be irrigated from site of application. This prepared composite hydrogel based hemostatic agent has potential application in low pressure bleeding sites.

壳聚糖（Cs）作为止血剂已用于控制止血。通过将血管收缩剂-硫酸铝钾（0.25％PA）和凝固活化剂-氯化钙（0.25％Ca）截留到Cs（2％）水凝胶中形成的复合水凝胶将增强Cs的止血性能。在这项工作中，所制备的复合水凝胶是可注射的，剪切稀化的，细胞和血液相容的。2％Cs-0.25％PA-0.25％Ca复合水凝胶通过加速RBC /血小板聚集和激活凝血级联反应而引起快速的血液凝结。此外，体内对大鼠肝和股动脉出血模型的研究表明，与市售止血剂-纤维蛋白相比，使用2％Cs-0.25％PA-0.25％Ca复合水凝胶可在更短的时间内（20±10 s，105±31 s）实现止血密封剂（77±26 s，204±58 s）和Floseal（76±15 s，218±46 s）。在体内毒理学研究中，复合水凝胶甚至在术后8周后仍显示出材料保留，因此应从应用部位冲洗过量的水凝胶。这种制备的基于复合水凝胶的止血剂在低压出血部位具有潜在的应用。